文献速递免疫规划传染病防控与疫情报告

2019/20年度流感疫苗中期效果:六项欧洲研究,2019年9月至2020年1月

Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020.
PubMed 文献 · Euro Surveill · 2020-01-01

六项欧洲研究采用检测阴性设计评估2019/20年度流感疫苗效果,覆盖10个国家、初级保健和医院环境,共纳入31537名患者。所有年龄组对任何流感疫苗效果点估计在初级保健为29%至61%,住院老年人为35%至60%;对A(H1N1)pdm09为48%至75%,对A(H3N2)在初级保健为-58%至57%、医院为-16%至60%,对B型流感为62%至83%(仅初级保健)。结论认为流感疫苗接种在2019/20流感季持续有益。

要点

  • 六项欧洲检测阴性设计研究评估2019/20年度流感疫苗效果。
  • 所有年龄组对任何流感疫苗效果:初级保健29%至61%,住院老年人35%至60%。
  • 对A(H3N2)疫苗效果点估计在初级保健为-58%至57%,医院为-16%至60%。

核心结论

  • 流感疫苗接种在2019/20流感季持续有益。
  • 稳健的季末疫苗效果估计和病毒基因特征结果可能有助于理解研究间流感亚型特异性结果的差异。

研究设计与样本

  • 六项欧洲研究采用检测阴性设计,覆盖10个国家,包括初级保健和医院环境。
  • 研究间在患者选择、数据来源、病例定义和纳入年龄组等方面存在差异。
  • 各研究采用逻辑回归调整潜在混杂因素,估计总体和流感亚型特异性疫苗效果。
  • 六项研究共招募31537名患者,其中5300例(17%)为病例,包含5310例感染。

主要发现

  • 5310例感染中大多数(4466例;84%)为甲型流感。
  • 所有年龄组对任何流感的疫苗效果点估计:初级保健为29%至61%,住院老年人(65岁及以上)为35%至60%。
  • 对A(H1N1)pdm09的疫苗效果点估计(所有年龄、两种环境)为48%至75%。
  • 对A(H3N2)的疫苗效果点估计:初级保健为-58%至57%,医院为-16%至60%。
  • 对乙型流感,所有年龄组疫苗效果为62%至83%(仅初级保健)。

局限性

  • 研究间在患者选择、数据来源、病例定义和纳入年龄组等其他研究特征方面存在差异。
  • 稳健的季末疫苗效果估计和病毒基因特征结果可能有助于理解研究间流感亚型特异性结果的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundInfluenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between September 2019 and January 2020.AimTo provide interim 2019/20 influenza vaccine effectiveness (VE) estimates from six European studies, covering 10 countries and both primary care and hospital settings.MethodsAll studies used the test-negative design, although there were some differences in other study characteristics, e.g. patient selection, data sources, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders.ResultsThere were 31,537 patients recruited across the six studies, of which 5,300 (17%) were cases with 5,310 infections. Most of these (4,466; 84%) were influenza A. The VE point estimates for all ages were 29% to 61% against any influenza in the primary care setting and 35% to 60% in hospitalised older adults (aged 65 years and over). The VE point estimates against A(H1N1)pdm09 (all ages, both settings) was 48% to 75%, and against A(H3N2) ranged from -58% to 57% (primary care) and -16% to 60% (hospital). Against influenza B, VE for all ages was 62% to 83% (primary care only).ConclusionsInfluenza vaccination is of continued benefit during the ongoing 2019/20 influenza season. Robust end-of-season VE estimates and genetic virus characterisation results may help understand the variability in influenza (sub)type-specific results across studies.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Rose A, Kissling E, Emborg HD, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Euro Surveill. 2020. PMID: 32183932. doi:10.2807/1560-7917.ES.2020.25.10.2000153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。